The FasT CAR-T (F-CAR-T) manufacturing platform in which T cell culture time is less than 24 hours was evaluated in two phase I clinical studies in patients with B-ALL using either CD19 or 19.22 Dual-CAR T cells (NCT03825718 and NCT04129099). Here, CD19 is linked to acute lymphoblastic leukemia.